Want to see GLUE full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly with the success of MRT-6160 and strategic agreement with Novartis. However, challenges such as lower than expected biomarker positivity in certain cancer cohorts and strategic shifts were noted. Overall, the positive developments and financial strength suggest a strong position for future growth.Company Guidance
MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Strategic Agreement with Novartis
Monte Rosa Therapeutics announced an exclusive strategic development agreement with Novartis for MRT-6160, aiming to accelerate and broaden its development.
NEK7 Program IND Submission On Track
NEK7 program is on track for an IND submission in the first half of the year, with promising preclinical data showing potent degradation of NEK7 and favorable safety profile.
Encouraging Data in Prostate Cancer
Initial data in the castration-resistant prostate cancer cohort showed one confirmed partial response and two stable diseases among three patients.
Strong Financial Position
Monte Rosa Therapeutics has a strong balance sheet with cash runway anticipated into 2028.
GLUE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GLUE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $20.39 | $19.81 | -2.84% |
Mar 17, 2026 | $16.35 | $16.03 | -1.96% |
Nov 06, 2025 | $12.31 | $13.01 | +5.69% |
Aug 07, 2025 | $4.36 | $4.23 | -2.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Monte Rosa Therapeutics, Inc. (GLUE) report earnings?
Monte Rosa Therapeutics, Inc. (GLUE) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Monte Rosa Therapeutics, Inc. (GLUE) earnings time?
Monte Rosa Therapeutics, Inc. (GLUE) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GLUE EPS forecast?
GLUE EPS forecast for the fiscal quarter 2026 (Q2) is -0.38.